Stock Scorecard
Stock Summary for 89bio Inc (ETNB) - $14.80 as of 10/8/2025 4:02:05 PM EST
Total Score
8 out of 30
Safety Score
35 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ETNB
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ETNB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ETNB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ETNB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ETNB (35 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ETNB
Financial Details for ETNB
Company Overview |
|
|---|---|
| Ticker | ETNB |
| Company Name | 89bio Inc |
| Country | USA |
| Description | 89bio, Inc. (ETNB) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for liver and cardiometabolic diseases, with a focus on addressing significant unmet medical needs. Based in San Francisco, California, the company is advancing a robust pipeline of treatments aimed at improving patient outcomes and quality of life. With a strategic emphasis on research and development, 89bio is well-positioned to make impactful contributions to the biopharmaceutical landscape while driving shareholder value. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/6/2025 |
Stock Price History |
|
| Last Day Price | 14.80 |
| Price 4 Years Ago | 13.07 |
| Last Day Price Updated | 10/8/2025 4:02:05 PM EST |
| Last Day Volume | 1,788,640 |
| Average Daily Volume | 6,824,039 |
| 52-Week High | 15.06 |
| 52-Week Low | 4.16 |
| Last Price to 52 Week Low | 255.77% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.22 |
| Sector PE | 41.70 |
| 5-Year Average PE | -5.32 |
| Free Cash Flow Ratio | 17.01 |
| Industry Free Cash Flow Ratio | 14.45 |
| Sector Free Cash Flow Ratio | 30.25 |
| Current Ratio Most Recent Quarter | 15.19 |
| Total Cash Per Share | 0.87 |
| Book Value Per Share Most Recent Quarter | 3.52 |
| Price to Book Ratio | 4.22 |
| Industry Price to Book Ratio | 29.58 |
| Sector Price to Book Ratio | 32.02 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 44.16 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.22 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 148,492,000 |
| Market Capitalization | 2,197,681,600 |
| Institutional Ownership | 110.28% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -158.16% |
| Reported EPS 12 Trailing Months | -3.69 |
| Reported EPS Past Year | -1.20 |
| Reported EPS Prior Year | -3.43 |
| Net Income Twelve Trailing Months | -450,206,000 |
| Net Income Past Year | -367,079,000 |
| Net Income Prior Year | -142,189,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 129,076,000 |
| Total Cash Past Year | 126,060,000 |
| Total Cash Prior Year | 316,161,000 |
| Net Cash Position Most Recent Quarter | 92,920,000 |
| Net Cash Position Past Year | 90,328,000 |
| Long Term Debt Past Year | 35,732,000 |
| Long Term Debt Prior Year | 24,795,000 |
| Total Debt Most Recent Quarter | 36,156,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.94 |
| Total Stockholder Equity Past Year | 400,789,000 |
| Total Stockholder Equity Prior Year | 536,306,000 |
| Total Stockholder Equity Most Recent Quarter | 521,733,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -439,188,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.96 |
| Free Cash Flow Past Year | -367,838,000 |
| Free Cash Flow Prior Year | -129,190,000 |
Options |
|
| Put/Call Ratio | 29.92 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.46 |
| MACD Signal | 1.35 |
| 20-Day Bollinger Lower Band | 6.38 |
| 20-Day Bollinger Middle Band | 10.70 |
| 20-Day Bollinger Upper Band | 15.02 |
| Beta | 1.26 |
| RSI | 79.25 |
| 50-Day SMA | 9.18 |
| 150-Day SMA | 11.02 |
| 200-Day SMA | 9.72 |
System |
|
| Modified | 10/6/2025 11:02:43 PM EST |